Clinical trials: Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis
M7824 in People With Recurrent Respiratory Papillomatosis
Background: Programmed cell death protein 1 (PD-L1) is a protein on the surface of cells. It regulates if a cell can be killed by immune system cells.
- Conditions
- Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis, Laryngeal Papilloma, Recurrent, Human Papilloma Virus
- Trial name
- NCT03707587
- Testing
- M7824
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Respiratory Papillomatosis
Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis (RRP) is the most common benign neoplasm of the larynx in the pediatric population. The impact of the disease on patients and families can be tremendous due to the need for frequent treatment.
- Trial name
- NCT00205374
- Testing
- Cidofovir
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Laryngeal Papilloma, Recurrent
Optiflow vs. Convential Anesthesia During Pediatric Laryngeal Papilloma Removal
This is a randomized cross over study of high flow oxygen delivery via nasal cannula vs. conventional tubeless anesthesia for patients undergoing dubulking surgery for laryngeal papilloma.
- Trial name
- NCT05215249
- Testing
- Transnasal humidified high-flow oxygen delivery
- Sponsor
- Massachusetts Eye and Ear Infirmary
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Recurrent Respiratory Papillomatosis
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP).
- Trial name
- NCT01020747
- Testing
- Avastin® (bevacizumab), Saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Recurrent Laryngeal Papillomatosis, Human Papilloma Virus
Human Papillomatosis Genotyping of Children in Thailand
The purpose of the present study was to identify risk factors for more severe juvenile Recurrent Respiratory Papillomatosis (RRP) through prospective evaluation of a pediatric population in Thailand by the employing a protocol…
- Trial name
- NCT01304966
- Testing
- biopsy
- Where
- 2 sites in Thailand
- Volunteers
- 15 people
- Sponsor
- Queen Sirikit National Institute of Child Health
Recurrent Respiratory Papillomatosis, Papillomavirus Infections
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
- Trial name
- NCT04724980
- Testing
- PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Precigen, Inc
Recurrent Respiratory Papillomatosis
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway.
- Trial name
- NCT01058317
- Testing
- Propranolol
- Sponsor
- Massachusetts Eye and Ear Infirmary
Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma
Avelumab for People With Recurrent Respiratory Papillomatosis
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. It can cause voice changes, airway compromise, pulmonary lesions, and cancers.
- Conditions
- Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Respiratory Papillomatosis
- Trial name
- NCT02859454
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Recurrent Respiratory Papillomatosis
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory…
- Trial name
- NCT02555800
- Testing
- Bevacizumab, Cidofovir
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
Recurrent Respiratory Papillomatosis
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
- Trial name
- NCT07317154
- Testing
- Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Squamous Papilloma of the Larynx
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis
Vaccines against human papillomaviruses are now commercially available. One of the commercial vaccine contains antigens of both LR HPV types which cause virtually all cases of RRP.
- Trial name
- NCT01375868
- Testing
- Silgard
- Where
- Czechia
- Volunteers
- 51 people
- Sponsor
- Ruth Tachezy, PhD.
Human Papilloma Virus, Recurrent Respiratory Papillomatosis
Merck IIT: RRP Pembro and Lenvatinib
This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP).
- Conditions
- Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease
- Trial name
- NCT04645602
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Papilloma, Recurrent Respiratory Papillomatosis
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis (RRP) causes wart-like lesions along the throat area and can obstruct the airway or become malignant. The cause has been related to specific types of Human Papillomavirus (HPV).
- Trial name
- NCT00038714
- Testing
- SGN-00101
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Nventa Biopharmaceuticals Corporation
Juvenile Recurrent Respiratory Papillomatosis
Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ")
Recurrent respiratory papillomatosis (RRP) is a rare disease. However, it is the most common benign laryngeal tumor in children. To date, no epidemiological data are available in France.
- Trial name
- REPA (NCT06000527)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Imagine Institute
Recurrent Respiratory Papillomatosis, Pulmonary Neoplasm
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11.
- Trial name
- NCT06412172
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Recurrent Respiratory Papillomatosis
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions.
- Trial name
- NCT01995721
- Testing
- 4-valent HPV vaccine
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- National Institute of Child Health, Hungary
Recurrent Respiratory Papillomatosis, Human Papilloma Virus
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) causes wart-like growths in the airway which can make it difficult to breathe, speak and carry out normal everyday activities.
- Trial name
- AIR:RRP (NCT03465280)
- Testing
- Microdebrider, Cold-steel surgery (forceps), Carbon dioxide laser
- Where
- 48 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Recurrent Respiratory Papillomatosis, Extra Oesophageal Reflux
Recurrent Respiratory Papillomatosis and Extraesophageal Reflux
The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).
- Conditions
- Recurrent Respiratory Papillomatosis, Extra Oesophageal Reflux, Laryngeal Cyst
- Trial name
- NCT02592902
- Testing
- Surgical collection of histology specimen, Performance of immunohistochemical analysis
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- University Hospital Ostrava